HIV latency reversing agents act through Tat post translational modifications

Retrovirology. 2018 May 11;15(1):36. doi: 10.1186/s12977-018-0421-6.

Abstract

Background: Different classes of latency reversing agents (LRAs) are being evaluated to measure their effects in reactivating HIV replication from latently infected cells. A limited number of studies have demonstrated additive effects of LRAs with the viral protein Tat in initiating transcription, but less is known about how LRAs interact with Tat, particularly through basic residues that may be post-translationally modified to alter the behaviour of Tat for processive transcription and co-transcriptional RNA processing.

Results: Here we show that various lysine and arginine mutations reduce the capacity of Tat to induce both transcription and mRNA splicing. The lysine 28 and lysine 50 residues of Tat, or the acetylation and methylation modifications of these basic amino acids, were essential for Tat transcriptional control, and also for the proviral expression effects elicited by histone deacetylase inhibitors (HDACi) or the bromodomain inhibitor JQ1. We also found that JQ1 was the only LRA tested that could induce HIV mRNA splicing in the absence of Tat, or rescue splicing for Tat lysine mutants in a BRD4-dependent manner.

Conclusions: Our data provide evidence that Tat activities in both co-transcriptional RNA processing together with transcriptional initiation and processivity are crucial during reactivation of latent HIV infection. The HDACi and JQ1 LRAs act with Tat to increase transcription, but JQ1 also enables post-transcriptional mRNA splicing. Tat residues K28 and K50, or their modifications through acetylation or methylation, are critical for LRAs that function in conjunction with Tat.

Keywords: HIV latency; LRA; Post-translational modification; Splicing; Tat.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Anti-HIV Agents / pharmacology
  • Azepines / pharmacology
  • Cell Cycle Proteins
  • Gene Expression Regulation, Viral / drug effects
  • HIV Infections / metabolism
  • HIV Infections / virology*
  • HIV-1 / drug effects*
  • HIV-1 / physiology*
  • Histone Deacetylase Inhibitors / pharmacology
  • Humans
  • Mutation
  • Nuclear Proteins / metabolism
  • Protein Processing, Post-Translational
  • RNA Splicing
  • Transcription Factors / metabolism
  • Transcription, Genetic / drug effects
  • Triazoles / pharmacology
  • Virus Activation / drug effects
  • Virus Latency / drug effects*
  • Virus Replication / drug effects
  • tat Gene Products, Human Immunodeficiency Virus / genetics*
  • tat Gene Products, Human Immunodeficiency Virus / metabolism*

Substances

  • (+)-JQ1 compound
  • Anti-HIV Agents
  • Azepines
  • BRD4 protein, human
  • Cell Cycle Proteins
  • Histone Deacetylase Inhibitors
  • Nuclear Proteins
  • Transcription Factors
  • Triazoles
  • tat Gene Products, Human Immunodeficiency Virus